Inflammatory bowel disease (IBD) poses complex issues in pregnancy, but with high-quality care excellent pregnancy outcomes are achievable. In this article, we review the current evidence and recommendations for pregnant women with IBD and aim to provide guidance for clinicians involved in their care. Many women with IBD have poor knowledge about pregnancy-related issues and a substantial minority remains voluntarily childless. Active IBD is associated with an increased risk of preterm birth, low for gestation weight and fetal loss. With the exception of methotrexate and tofacitinib the risk of a flare outweighs the risk of IBD medication and maintenance of remission from IBD should be the main of care. Most women with IBD will experience a normal pregnancy and can have a vaginal delivery. Active perianal Crohn’s disease is an absolute and ileal pouch surgery a relative indication for a caesarean section. Breast feeding is beneficial to the infant and the risk from most IBD medications is negligible.
Introduction Characterised by chronic inflammation of the gastrointestinal tract, inflammatory bowel disease (IBD) symptoms including diarrhoea, abdominal pain and fatigue can significantly impact patient’s quality of life. Therapeutic developments in the last 20 years have revolutionised treatment. However, clinical trials and real-world data show primary non-response rates up to 40%. A significant challenge is an inability to predict which treatment will benefit individual patients. Current understanding of IBD pathogenesis implicates complex interactions between host genetics and the gut microbiome. Most cohorts studying the gut microbiota to date have been underpowered, examined single treatments and produced heterogeneous results. Lack of cross-treatment comparisons and well-powered independent replication cohorts hampers the ability to infer real-world utility of predictive signatures. IBD-RESPONSE will use multi-omic data to create a predictive tool for treatment response. Future patient benefit may include development of biomarker-based treatment stratification or manipulation of intestinal microbial targets. IBD-RESPONSE and downstream studies have the potential to improve quality of life, reduce patient risk and reduce expenditure on ineffective treatments. Methods and analysis This prospective, multicentre, observational study will identify and validate a predictive model for response to advanced IBD therapies, incorporating gut microbiome, metabolome, single-cell transcriptome, human genome, dietary and clinical data. 1325 participants commencing advanced therapies will be recruited from ~40 UK sites. Data will be collected at baseline, week 14 and week 54. The primary outcome is week 14 clinical response. Secondary outcomes include clinical remission, loss of response in week 14 responders, corticosteroid-free response/remission, time to treatment escalation and change in patient-reported outcome measures. Ethics and dissemination Ethical approval was obtained from the Wales Research Ethics Committee 5 (ref: 21/WA/0228). Recruitment is ongoing. Following study completion, results will be submitted for publication in peer-reviewed journals and presented at scientific meetings. Publications will be summarised at www.ibd-response.co.uk. Trial registration number ISRCTN96296121.
An increasing amount of distributed real-time systems and other critical infrastructure now rely on Data Distribution Service (DDS) middleware for timely dissementation of data between system nodes. While DDS has been designed specifically for use in distributed real-time systems and exposes a number of QoS properties to programmers, DDS fails to lift time fully into the programming abstraction. The reason for this is simple: DDS cannot directly control the underlying network to ensure that messages always arrive to their destination on time. In this paper we describe a prototype system that uses the OpenFlow SDN protocol to automatically and transparently learn the QoS requirements of DDS participants. Based on the QoS requirements, our system will manipulate the low-level packet forwarding rules in the network to ensure that the QoS requirements are always satisfied. We use real OpenFlow hardware to evaluate how well our prototype is able to manage network contention and guarantee the requested QoS. Additionally, we evaluate how well the reliability and resilience features of a real DDS implementation is able to compensate for network contention on an unmanaged (i.e., normal) ethernet. To the best of our knowledge, this is the first evaluation of performance DDS under extreme network contention conditions.
Large-scale multicentre studies are needed to understand complex relationships between the gut microbiota, health and disease. Interrogating the mucosal microbiota may identify important biology not captured by stool analysis. Gold standard tissue cryopreservation ('flash freezing') limits large-scale study feasibility. We aimed to compare gut microbiota in gold standard and pragmatic mucosal biopsy storage conditions. We collected endoscopic recto-sigmoid biopsies from 20 adults with inflammatory bowel disease. Biopsies were preserved using three methods: (i) flash freezing (most proximal and distal biopsy sites); (ii) nucleic acid preservative reagents (QIAGEN Allprotect®, Invitrogen RNAlater™, and Zymo DNA/RNA Shield™); and (iii) formalin fixation with paraffin embedding (FFPE), which is used to preserve tissue for clinical histopathology within healthcare settings. Microbiota were sequenced on the MiSeq platform (V4 region, 16S rRNA gene). Tissue microbiota were consistent between most proximal and distal tissue suggesting any within-patient variation observed reflected storage condition, not biopsy location. There was no significant difference in alpha-diversity or microbial community profiles of reagent-preserved versus gold standard tissue. FFPE community structure was significantly dissimilar to other tissue samples, driven by differential relative abundance of obligate gut anaerobes; Faecalibacterium, Anaerostipes and Lachnospiraceae. Despite these differences, tissue microbiota grouped by participant regardless of preservation and storage conditions. Preservative reagents offer a convenient alternative to flash freezing tissue in prospective large-scale mucosal microbiota studies. Whilst less comparable, FFPE provides potential for retrospective microbiota studies using historical samples. Medical Research Council (MR/T032162/1) and The Leona M. and Harry B. Helmsley Charitable Trust (G-2002-04255).
The emerging network-enabled medical devices impose new challenges for the safety assurance of medical cyber-physical systems (MCPS). In this paper, we present a case study of building a high-level safety argument for a patient-controlled analgesia (PCA) closed-loop system, with the purpose of exploring potential methodologies for assuring the safety of MCPS.
Background: Dye chromoendoscopy (DCE) is the recommended endoscopic modality for dysplasia detection in inflammatory bowel disease (IBD) surveillance, but randomised trials suggest comparable performance with virtual chromoendoscopy (VCE) and high-definition white light endoscopy (WLE). This multicentre UK study evaluated the association between modality and dysplasia detection in routine practice. Methods: We performed a multicentre study across six UK centres, identifying adults with ulcerative colitis (UC), colonic Crohn’s disease (CD), or primary sclerosing cholangitis associated IBD (PSC-IBD) undergoing surveillance colonoscopy between 2019-2024. Outcomes included dysplasia detection rate (DDR), neoplasia detection rate (NDR) and total lesion detection yield. Multivariable regression models and inverse probability weighting (IPW) analysis were used to evaluate detection rates taking into consideration recognised variables that associate with dysplasia risk. Findings: We included 3643 colonoscopies in 2831 patients (UC 54%, CD 22%, PSC-IBD 24%). The most frequently used modality was WLE (50%) followed by DCE (35%) and VCE (15%), with inter-centre variation in modality selection, dedicated surveillance lists, and withdrawal time. Raw DDR were higher with DCE (10%) and VCE (10%) vs. WLE (7%, p=0·012). On multivariable adjustment, modality was not independently associated with DDR. However, when variables were weighted with IPW, there was a numerically higher DDR with VCE (OR 1·60, 95% CI 1.00-2.58; p=0·051). VCE associated with higher NDR allowing the identification of more serrated and hyperplastic lesions. Longer withdrawal time, previous colorectal neoplasia, bowel preparation quality, and surveillance expertise were also associated with increased detection rates, whereas active inflammation had the opposite effect. Interpretation: In this large, multicentre study of clinical practice DCE was not superior to VCE or WLE for dysplasia detection. Identifying patients who will benefit most from surveillance and providing access to dedicated lists performed by experienced endoscopists with sufficient withdrawal time are key to increasing lesion detection in surveillance programmes.